

MATHIEU FRÉCHIN APPOINTED CHIEF AI OFFICER AT NANOLIVE

Tolochenaz, Switzerland — June 23rd, 2025 — Nanolive, a pioneer in live-cell imaging and quantitative biology, is proud to announce the promotion of Mathieu Fréchin to Chief AI Officer (CAIO).

Mathieu, a seasoned expert in quantitative biology and artificial intelligence, has played a pivotal role in shaping Nanolive’s technological trajectory over the past eight years. With a strong academic foundation—including a PhD in biophysics and extensive research at ETH Zurich—Mathieu bridges deep biological understanding with cutting-edge AI applications.

In his previous role as Director of AI and Biology, Mathieu led the development of EVE Explorer—Nanolive’s next-generation AI data platform. The platform unlocks the most advanced live-cell insights in the world, enabling scientists to study living cells in real time, with unprecedented clarity and depth.

As CAIO, Mathieu will continue to lead innovation at the intersection of cell biology and AI, ensuring that Nanolive stays at the forefront of the life sciences revolution.

Mathieu Fréchin, CAIO of Nanolive, stated:

“Biology is no longer a single-discipline science. At Nanolive, we build bridges between physics, AI, and cell biology to decipher what living systems are truly telling us. My goal is to turn the complexity of our images into predictive, actionable insight to help our clients to develop the next generation of therapies.”

Yann Cotte, CEO of Nanolive, stated:

“Mathieu’s unique ability to integrate biology, physics, and AI is at the heart of Nanolive’s mission: making live cells the key to next generation health discoveries and therapies. From building our AI capabilities from scratch to launching EVE Explorer, Mathieu has proven to be a visionary leader who turns complexity into impact. His leadership will be instrumental in bringing the power of live-cell data into the hands of every scientist and innovator shaping the future of healthcare.”

This leadership appointment marks a major milestone in Nanolive’s ambition to enable new frontiers in drug discovery, immunotherapy, and precision medicine—powered by living cells.

ABOUT NANOLIVE SA

Nanolive develops breakthrough live-cell imaging platforms and AI-driven solutions to observe and analyze living cells in real time, without labels or damage. Our mission is to make live cells the key to next generation health discoveries and therapies.

Media Contact:

Nanolive SA

Route de Lully, 5B

1131 Tolochenaz

Switzerland

lookinginsidelife@nanolive.ch



Photo by Blaise Kormann